Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Medulloblastoma 2Glioblastoma 2Ependymoma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Diffuse Intrinsic Pontine Glioma 1Adenocarcinoma 1

Interventions

Oxaliplatin 19pembrolizumab 13Fluorouracil 12Leucovorin 11Capecitabine 11Paclitaxel 10Gemcitabine 9Docetaxel 8zolbetuximab 6cemiplimab 6Cisplatin 6Albumin-Bound Paclitaxel 6durvalumab 5Ramucirumab 5Radiotherapy 5130-nm albumin-bound paclitaxel 5Irinotecan 4Cyclophosphamide 4trastuzumab deruxtecan 3tislelizumab 3lenvatinib 3enzalutamide 3darolutamide 3Trastuzumab 3Taxes 3S 1 (combination) 3Radiosurgery 3Pemetrexed 3Nivolumab 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × 1-methyltryptophan × 1 year × Clear all
NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Lumos Pharma

Phase 1/2 Completed
157 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡